GENERAL COMMENTS
Thank you for asking me to review this paper, which describes the development of a priority setting partnership PSP) in Liver and gallbladder disorders. I should start by saying that I am generally a fan of James Lind Alliance Priority Setting Partnerships, and feel they play an important role in identifying priority areas for research, so I was expecting to like this paper.
Having read the manuscript I have some concerns that I think would be worth considering prior to publication. Major concerns: 1. Scope of the project -the PSP is described as addressing uncertainties for both liver and gall bladder disorders, but in actual fact it turned into a PSP of liver conditions due to the make up of participants in the latter stages. Given this considerable bias in favour of liver conditions throughout this PSP, I wonder if it would be better to describe this work as a liver disorders PSP only? (This might require some re-analysis, but would I think better reflect what actually happened). 2. Although this is a JLA PSP, with an independent JLA advisor as part of the team, I am concerned that something has gone awry in relation to the patient involvement aspects of this project. There appear to have been very few patients involved int eh Steering Group (although I wasn't quite clear how many were involved), and looking at the wording of some the prioritised questions, it is clear that lay input was insufficient in formulating the wording of these uncertainties (usually a key part of the process). As a result, I am concerned that patients taking part in the Delphi would not have been able to understand many of the uncertainties that they were voting on (as there are so many unexplained medical terms and diagnoses).
3. I am also concerned that something quite unusual has happened between the initial survey and the shortlisting of the questions.
• There was an unusually small number of responses from healthcare professionals in the initial survey (13) -it is not clear why this was • More uncertainties were identified from the existing research literate (219) than from the survey (209) -with the results that it is the research community that has potentially driven the uncertainties included in this PSP (in a JLA PSP researchers are normally excluded from the process as it is the voice of patients and the professionals who treat them that the process is trying to identify • Despite small numbers of participants taking part (139 in total for survey 1) -there were 428 unique uncertainties after clumping and re-wording -this seems to be unusually high -it is generally at this stage that a lot of work takes place (involving patients and HCPs) to develop and refine the indicative uncertainties based on the submitted questions -usually there would be approximately 50 at the end of this stage.
• To reduce the number to approx. 50, it appears that ranked preferences of the Steering Group members were used to select the topics to be taken forward into the Delphi. I'm sorry if I've misunderstood, but why was this approach used rather than the more usual approach of choosing the most commonly asked questions (ie rank order of frequency from the initial survey?). It seems to be very open to bias and personal interests.
3. The authors chose not to follow the usual JLA process of having a final workshop (which I have some sympathy with), and so I was interested to read about the e-Delphi approach. Just a few reflections on this stage:
• There was a roughly equal split of patients and HCPs at this stage (which is good) -but there did seem to be a heavy bias towards liver specialists in the HCP group -which would explain why so many of the final top 10 relate to liver disease.
• In the patient participants, there were members of the general public as well as people with related diseases -this seems od d and would be helpful to know how many of the patients fell into this category.
• For all stages of the process it would be helpful to have included a table summarising participant characteristics.
• Participants in the e-Delphi were able to add in topics that they felt were important (which added a further 22) -whilst this is normal for a stand-alone e-Delphi, it seems an odd approach within the confines of a PSP when a great deal of work has already gone into prioritising the short-list of uncertainties.
• The final top 10 included no uncertainties on diagnostic uncertainty -I would have found it helpful to know how prominent diagnostic questions were at the earlier stage of the process -as this is the kind of thing that might typically have been picked out at the final workshop stage (ie there are no questions from a whole broad category -is that OK?) Possibly the results for each stage could be presented as the number falling into each category of treatment, prevention and diagnosis?
• The final top 10 is extremely disappointing as 6 of the top 10 are essentially a non-specific call for further research into 6 different conditions -I am not sure how this really helps to progress the field or helps to target research? (It feels as though each of these conditions needs its own PSP!). At this late stage, I'm not sure what can be done -but I wonder if it would be possible to present the results in a more nuanced way? I'm also intrigued to see how patients voted as I would be surprised if most have even heard of any of these conditions (unless they happen to have it). It would be useful to see the results presented for patients and HCPs separately and combined throughout.
4. The discussion is very long and could benefit from reduction.
I am sorry to be so down on this paper. My apologies if I have caused offence -I only mean to try and help.
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GENERAL COMMENTS
Thank-you for asking me to review this paper reporting on a rigorous and thoughtful research prioritisation exercise in nonalcohol related liver and gallbladder disease. The final list of priorities will provide a good focus for generating future research and the inclusion of the PICO for each question will set the scene when designing new research in this field.
The major limitation of the paper is openly acknowledged, namely that patient representation and clinician participation was predominantly in the area of liver disease. The Delphi process itself has been carried out to high standards.
There are some points to be addressed that may strengthen the manuscript prior to publication:
1. Illustrating the value of PSPs in generating research with examples from other field will provide broader appeal for BMJ Open readership.
2. Initial review of literature combined with a survey to generate research priorities is a strength, as is the introduction of novel research questions at Delphi stage (participants could contribute up to two new questions). It is not clear why the steering group chose to limit the interim list to 48 questions as that process could have been done by all in the first Delphi stage, and the reasons for this decision should be clear.
3. How were participants approached e.g. email, letter, social media, etc? 42 participants appears rather few to represent both clinicians and HCPs (especially as 126 participants generated questions in the survey) for such a broad subject and merits discussion.
4. Was the Delphi consensus carried out using paper or electronic forms. If electronic, which software were used? What strategies were employed to avoid "ambushing" e.g. inclusion only if completion of prioritisation of all questions in any round; random order of questions for each participant in each round.
5. Was there heterogeneity in Delphi responses e.g. if the majority ranked a question 7-9, did the rest use 4-6 or was the group polarised and they only scored 1-3? This information is particularly important for the 4 included questions which did not meet consensus criteria.
6. Table 2 and the first part of the discussion both concentrate on RCTs without any reference to the IDEAL Collaboration principles of developing research questions. Table 2 in particular illustrates that the RCTs available have not measured the outcomes prioritised, and so stipulating further RCTs with different measured outcomes perhaps may not automatically advance the field.
Having an expert in methodology and trial design comment on "next steps" may be helpful. Please leave your comments for the authors below This is a unique, he document that can be a valuable contribution. This is a breathtaking project in its scope and mission. Really amazing work. Basically, this is a position statement on the unmet needs in liver disease research. The Delphi methods are clear, appropriate, and exacting. The document is really quite overwhelming and is certain to never be read in its entirety -something of which I am sure the authors are aware.
Author team: Thank you for your positive comments.
This reviewer has three minor concerns:
-One, the research landscape proposed is technical and feels like the concerns of patient representatives may not have been fully captured. In the top 10 there are things like optimal immunosupression of liver transplant and machine perfusion of allografts. Is it possible that the methods (80% of respondants feel the qeustion is very important) obscures an important 20% minority. Can there be a top 10 question if several people rate it as a 1-3 (and did that ever happen? And why are all the top questions dominated by 'hard' clinical outcomes like disease progression when surely symptoms/HRQOL are critical outcomes in, say, PBC?
Author team: We agree that symptoms, which are important to patients, did not make it to the top 10 research priorities despite patients making up a significant proportion of the Delphi panel. We have now included the information on whether any of the top 10 were considered least important by the Delphi panel members.
-Two, can the tables be made more user friendly. I am not sure how. One suggestion, more columns and short-hand for concepts
Author team: We think that this refers to the appendix file 1. We anticipate that this is looked at greater depth by people who want to know more about outcomes. We feel that using shorthand can actually delay the processing by the intended audience rather than facilitate.
-Three, the next steps part may need another look. For instance, one or two suggestions are for "systematic reviews" which would seem to contradict the 'lack of evidence to answer the question' inclusion criterion. Beyond that there are a lot of calls for "RCTs". It is very easy to recommend an RCT and perhaps that is really not needed. Rather it would be best to give guidance: which patients (if you say PBC, do you mean refractory, urso naive, early or late); which outcomes -not just "clinical outcomes"; if HRQOL, which tool? And so on.
Author team: We have used the JLA definition of uncertainty: "Research questions were considered 'answered' when recent high-quality systematic reviews (based on low risk of bias studies) concluded that further research was not required. Removal of such 'answered' research questions was planned. The remaining questions were 'uncertainties'". While we have performed the basic next step in addressing the uncertainty, the more granular information requested is a major undertaking and is a separate policy guidance on its own. Thank you for asking me to review this paper, which describes the development of a priority setting partnership PSP) in Liver and gallbladder disorders. I should start by saying that I am generally a fan of James Lind Alliance Priority Setting Partnerships, and feel they play an important role in identifying priority areas for research, so I was expecting to like this paper.
Having read the manuscript I have some concerns that I think would be worth considering prior to publication.
We thank the reviewer for their interest in priority setting partnerships.
Major concerns:
1. Scope of the project -the PSP is described as addressing uncertainties for both liver and gall bladder disorders, but in actual fact it turned into a PSP of liver conditions due to the make up of participants in the latter stages. Given this considerable bias in favour of liver conditions throughout this PSP, I wonder if it would be better to describe this work as a liver disorders PSP only? (This might require some reanalysis, but would I think better reflect what actually happened).
Author team:
• We are flexible on the title of the paper; however, our preference is to retain the scope as was originally intended and not as it happened. We have discussed this in detail and have highlighted that we need other priority setting partnerships for liver transplantation and gallbladder disorders. Changing the title would mean that the title does not align with our objectives, results or discussion.
2. Although this is a JLA PSP, with an independent JLA advisor as part of the team, I am concerned that something has gone awry in relation to the patient involvement aspects of this project. There appear to have been very few patients involved int eh Steering Group (although I wasn't quite clear how many were involved), and looking at the wording of some the prioritised questions, it is clear that lay input was insufficient in formulating the wording of these uncertainties (usually a key part of the process). As a result, I am concerned that patients taking part in the Delphi would not have been able to understand many of the uncertainties that they were voting on (as there are so many unexplained medical terms and diagnoses).
• There were two patient representatives involved in the steering group. It was based on the patient representative (AL) objecting to the final face-to-face meeting because of the power imbalance between the patients and clinicians in the previous JLA-PSP that he was involved in, that we moved from the traditional JLA process which culminates in large and small group discussions to Delphi process. In fact, one of the underpinning assumptions of non-anonymous group discussions are that individuals are valuable sources of information and are capable of expressing their own feelings (Halcomb, E. J., Gholizadeh, L. , DiGiacomo, M. , Phillips, J. Otherwise, he would have objected to this method at the protocol stage. All the suggestions of PPI representatives on the panel were implemented in phrasing the questions for the second round survey to ensure that they were understood by the patients, carers, and public. The respondents were also given the opportunities to clarify doubts related to the questions by email or an online forum.
• There was an unusually small number of responses from healthcare professionals in the initial survey (13) -it is not clear why this was
• More uncertainties were identified from the existing research literate (219) than from the survey (209) -with the results that it is the research community that has potentially driven the uncertainties included in this PSP (in a JLA PSP researchers are normally excluded from the process as it is the voice of patients and the professionals who treat them that the process is trying to identify
• Despite small numbers of participants taking part (139 in total for survey 1) -there were 428 unique uncertainties after clumping and re-wording -this seems to be unusually high -it is generally at this stage that a lot of work takes place (involving patients and HCPs) to develop and refine the indicative uncertainties based on the submitted questions -usually there would be approximately 50 at the end of this stage.
• We think that the lack of interest among clinicians was because of the lack of awareness of the importance of using patient-involved top 10 research priorities. Previous studies have shown that there is a mismatch between research questions that are considered important jointly by patients, carers, and healthcare professionals and the research performed in many fields of medicine ( We sent links to the clinicians through newsletters in British Society of Gastroenterology which would cover the scope of this JLA.
• As we mention in the manuscript, the domination by chronic liver diseases may be because of the high motivation to support research from those groups (given that there are few effective treatments and there is great uncertainty around this issue) compared to other diseases for which definitive treatments exist. Therefore, we did a thorough search of literature to identify priorities that were not covered.
• Because of the wide scope of this project (we discuss this as a limitation), we identified lot of unique uncertainties which we provided in the appendix. Most of the questions were asked only a few times and it was important to include questions that were considered important by different stakeholders for the second survey. Therefore, we had to shortlist this to 50 questions to conduct the second survey. We had to use the steering committee to perform this.
• The final top 10 is extremely disappointing as 6 of the top 10 are essentially a non-specific call for further research into 6 different conditions -I am not sure how this really helps to progress the field or helps to target research? (It feels as though each of these conditions needs its own PSP!). At this late stage, I'm not sure what can be done -but I wonder if it would be possible to present the results in a more nuanced way?
I'm also intrigued to see how patients voted as I would be surprised if most have even heard of any of these conditions (unless they happen to have it). It would be useful to see the results presented for patients and HCPs separately and combined throughout.
Author replies:
• The number of liver specialists reflect the steering committee decision to include more 'medical' questions than 'surgical' questions.
• To protect the identity and not reveal whether the Delphi panel members had any liver disease, we have not mentioned this. Confidentially, we can inform that 14/16 patients, carers, and public were patients and carers.
• We have now provided which category dropped out in each round in the beginning of final priorities section which covers the Delphi process.
• We allowed people to add new questions to reflect the change in the process and to ensure that questions considered important by the wider Delphi panel members were not missed.
• We did not separate the prevention and treatment as separate categories as these are categorised as interventional. In the appendix 1 and 2, we have the complete list of research questions and the interim priorities -these are clearly identified as diagnosis or screening. Unfortunately, none of them made it to the top 10.
• As we discuss, we might need additional priority setting partnerships for many conditions. However, we do not think one is needed for every single chronic liver disease as some of the top 10 priorities are broad and can include different comparisons.
• We have now provided the information for healthcare professionals and patients/carers/public in the appendix 4.
